Announcements Trials
Browse Landscape

Status

Completed 191Terminated 44Unknown 15Withdrawn 12Recruiting 7Active not recruiting 4Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Lymphoid 4Plasma cell 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Melanoma 16Lymphoma, T-Cell, Cutaneous 2Glioma 2Glioblastoma 2Uveal Melanoma 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Keratosis 1Hodgkin Disease 1Hematologic Diseases 1Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Carcinoma 1Breast Neoplasms 1Bowen's Disease 1

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Hodgkin Disease × Dermatologic × Clear all
NCT01196208 2020-09-21

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Seagen Inc.

No longer available
DermatologicLymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡